Who is sponsoring NCT04796597?

NCT04796597 is sponsored by Wyss Center for Bio and Neuroengineering.

What drugs are being tested in NCT04796597?

Interventions in NCT04796597: Subcutaneous implantation of Epios sub-scalp leads.

Is NCT04796597 still recruiting?

NCT04796597 is currently completed. Last updated 14 November 2023.

Last reviewed 2023-11-14 · How we verify

NCT04796597

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Early Feasibility Study on Epios Leads

Completed NA Last updated 14 November 2023

What this trial tests

NA trial testing Subcutaneous implantation of Epios sub-scalp leads in Epilepsy in 10 participants. Completed in 2 November 2023.

Timeline

23 March 2021

Primary endpoint
7 July 2023

2 November 2023

Quick facts

Lead sponsor	Wyss Center for Bio and Neuroengineering
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	device feasibility
Enrollment	10
Start date	23 March 2021
Primary completion	7 July 2023
Estimated completion	2 November 2023
Sites	1 location across Switzerland

Drugs / interventions tested

Subcutaneous implantation of Epios sub-scalp leads

Conditions studied

Epilepsy — all drugs for Epilepsy →

Sponsor

Wyss Center for Bio and Neuroengineering

Who can join

18 and older, any sex, with Epilepsy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Epios early feasibility study aims to explore the uses of novel sub-scalp lead devices in the detection of epileptic seizures. Epios leads are inserted subcutaneously through dedicated tunneling toolkits and have been designed for continuous EEG recording in inpatients. This clinical investigation is part of a stepwise program to validate the entire Epios system and it starts with the validation of the Epios leads alone in this two steps study.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Feasibility, Safety, and Performance of Full-Head Subscalp EEG Using Minimally Invasive Electrode Implantation.
van Maren E, Alnes SL, Ramos da Cruz J, Sobolewski A, et al · · 2024 · cited 7× · PMID 38843489 · DOI 10.1212/wnl.0000000000209428
Novel subscalp and intracranial devices to wirelessly record and analyze continuous EEG in unsedated, behaving dogs in their natural environments: A new paradigm in canine epilepsy research.
Löscher W, Worrell GA. · · 2022 · cited 4× · PMID 36337210 · DOI 10.3389/fvets.2022.1014269

Verify or expand the search:

Other recruiting trials for Epilepsy

Currently open trials in the same condition.

NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
NCT07224191 — Hippocampal Oscillations During Exploration · NA · recruiting
NCT07219407 — A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures · Phase 2 · recruiting
NCT07417280 — LIFUS For Neurological Disorders · NA · recruiting
NCT07490769 — Levetiracetam Three Times Daily in Epilepsy · Phase 3 · recruiting

Other Wyss Center for Bio and Neuroengineering trials

Trials by the same sponsor.

NCT04448483 — Clinical Study for Upper Limb Motor Restoration in Chronic Stroke Patients Using Personalized Neuro-technologies · NA · completed
NCT02932839 — Investigating the Neuronal Bases of Epilepsy With Micro-electrode Arrays in Candidates for Epilepsy Surgery · NA · completed
NCT05737888 — Physiological Regulation of Chronic Tinnitus · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04796597 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Wyss Center for Bio and Neuroengineering
Last refreshed: 14 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04796597.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing